I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 5 studies | 32% ± 11% | |
| enterocyte | 4 studies | 21% ± 3% | |
| basal cell | 4 studies | 26% ± 7% | |
| ciliated cell | 3 studies | 20% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 5 studies | 32% ± 11% | |
| enterocyte | 4 studies | 21% ± 3% | |
| basal cell | 4 studies | 26% ± 7% | |
| ciliated cell | 3 studies | 20% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| intestine | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 100% | 1949.81 | 653 / 653 | 100% | 30.97 | 604 / 605 |
| prostate | 100% | 1858.02 | 245 / 245 | 100% | 23.45 | 501 / 502 |
| liver | 100% | 4447.26 | 226 / 226 | 100% | 33.63 | 405 / 406 |
| esophagus | 100% | 3310.69 | 1444 / 1445 | 99% | 15.16 | 182 / 183 |
| lung | 100% | 1506.94 | 578 / 578 | 99% | 15.24 | 1146 / 1155 |
| breast | 100% | 1695.20 | 459 / 459 | 99% | 20.01 | 1108 / 1118 |
| skin | 100% | 2831.12 | 1803 / 1809 | 99% | 17.71 | 469 / 472 |
| uterus | 100% | 1519.26 | 170 / 170 | 99% | 26.97 | 454 / 459 |
| ovary | 100% | 1167.60 | 180 / 180 | 99% | 13.64 | 424 / 430 |
| bladder | 100% | 1237.48 | 21 / 21 | 98% | 18.74 | 496 / 504 |
| intestine | 100% | 1817.73 | 966 / 966 | 98% | 15.57 | 518 / 527 |
| kidney | 100% | 1978.67 | 89 / 89 | 98% | 14.71 | 884 / 901 |
| stomach | 100% | 1169.81 | 358 / 359 | 98% | 11.81 | 279 / 286 |
| pancreas | 98% | 721.23 | 321 / 328 | 99% | 20.43 | 176 / 178 |
| brain | 95% | 744.83 | 2521 / 2642 | 100% | 13.37 | 705 / 705 |
| adrenal gland | 100% | 1748.91 | 258 / 258 | 92% | 13.24 | 211 / 230 |
| eye | 0% | 0 | 0 / 0 | 100% | 20.01 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 16.97 | 29 / 29 |
| spleen | 100% | 2081.82 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 30.21 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.04 | 1 / 1 |
| blood vessel | 100% | 1490.75 | 1330 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 1261.82 | 1199 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 96% | 1048.40 | 893 / 929 | 0% | 0 | 0 / 0 |
| heart | 82% | 475.34 | 707 / 861 | 0% | 0 | 0 / 0 |
| muscle | 17% | 79.22 | 138 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0047045 | Molecular function | testosterone 17-beta-dehydrogenase (NADP+) activity |
| GO_0004090 | Molecular function | carbonyl reductase (NADPH) activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0016616 | Molecular function | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor |
| Gene name | DHRS1 |
| Protein name | Dehydrogenase/reductase (SDR family) member 1, isoform CRA_b (Dehydrogenase/reductase 1) Alternative protein DHRS1 Dehydrogenase/reductase SDR family member 1 (EC 1.1.1.-) (Short chain dehydrogenase/reductase family 19C member 1) (Protein SDR19C1) |
| Synonyms | hCG_40190 SDR19C1 |
| Description | FUNCTION: NADPH-dependent oxidoreductase which catalyzes the reduction of steroids (estrone, androstene-3,17-dione and cortisone) as well as prostaglandin E1, isatin and xenobiotics in vitro . May have a role in steroid and/or xenobiotic metabolism . . |
| Accessions | Q96LJ7 ENST00000288111.12 ENST00000558340.1 ENST00000644514.2 L0R4X0 ENST00000396813.5 H0YNC2 ENST00000647514.1 |
